COMPANY

Evrys Bio

HQ: Doylestown, PA source · evrysbio.com ↗ · Mid-Atlantic

Location: Doylestown, PA · source · Jan 5, 2022

Profile checked Oct 10, 2026

16NIH grants

Funding and NIH signals

NIH award NIH awarded $962K (SBIR Phase II 5R44AI157725-04, continuation, notice Sep 10, 2026). NIH RePORTER 5R44AI157725-04 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · NIH RePORTER 5R44AI157725-04
  Organization: EVRYS BIO, INC.; City/State: DOYLESTOWN, PA; Project number: 5R44AI157725-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 961797; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 10, 2026 Grant Government grant — SBIR: $961,797 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jun 30, 2025 Grant Government grant — SBIR: $961,797 (annual award, as published), announced Jun 30, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Grant Government grant — SBIR: $978,771 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Sep 10, 2026 Government grant — SBIR: $961,797 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jun 30, 2025 Government grant — SBIR: $961,797 (annual award, as published), announced Jun 30, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Government grant — SBIR: $978,771 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 16

Annual award amounts. Total $11.0M.

Jul 18, 2024 NIH award 4R44AI157725-02 FY2024: $961,797 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. Development of a host-targeted antiviral as source ↗
Apr 8, 2024 NIH award 5R44AI114079-06 FY2024: $983,882 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple opportu source ↗
Apr 10, 2023 NIH award 2R44AI114079-05 FY2023: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple opportu source ↗
Aug 20, 2021 NIH award 1R44AI157725-01A1 FY2021: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. Development of a host-targeted antiviral a source ↗
Aug 13, 2021 NIH award 5R44AI114079-04 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple oppor source ↗
Jul 22, 2020 NIH award 3R44AI114079-03S1 FY2020: $901,086 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple oppor source ↗
Jul 16, 2020 NIH award 5R44AI114079-03 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple oppor source ↗
Jul 31, 2019 NIH award 2R44AI114079-02 FY2019: $999,997 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A single antiviral to treat multiple opportu source ↗
Jul 23, 2019 NIH award 5R44AI122488-03 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRA source ↗
Aug 14, 2018 NIH award 4R44AI122488-02 FY2018: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRA source ↗
Aug 5, 2016 NIH award 1R44AI122488-01 FY2016: $304,858 awarded for that fiscal year; activity R44 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS source ↗
Jul 13, 2016 NIH award 5R01AI101080-04 FY2016: $437,500 awarded for that fiscal year; activity R01 (OTHER_NIH); PI MURPHY, EAIN A; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. Mechanisms of Human Cytomegalovirus Latency source ↗
Jul 1, 2015 NIH award 7R01AI101080-03 FY2015: $437,500 awarded for that fiscal year; activity R01 (OTHER_NIH); PI MURPHY, EAIN A; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. Mechanisms of Human Cytomegalovirus Latency source ↗
Feb 4, 2015 NIH award 1R43AI118232-01 FY2015: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI REMISZEWSKI, STACY; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. An Antiviral to Treat Progressive Multifocal source ↗
Jun 4, 2014 NIH award 1R43AI114079-01 FY2014: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI KOYUNCU, EMRE; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. A Single Antiviral to Treat Multiple Opportunisti source ↗
Feb 5, 2014 NIH award 1R43AI110048-01 FY2014: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI KOYUNCU, EMRE; recipient as written: EVRYS BIO, INC., DOYLESTOWN, PA. Host-Targeted Mechanism of Action for Treatment o source ↗